ArticleGenetics in medicine : official journal of the American College of Medical Genetics
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer.
Article in Genetics in medicine : official journal of the American College of Medical Genetics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Pooled it
- Is individualized medicine more cost-effective? A systematic review.PharmacoEconomics · 2014Pooled it
- Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.Contemporary clinical trials · 2014Trial
- Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece.ESMO gastrointestinal oncology · 2025Article
- Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome.Gastroenterology · 2021Article
- Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Article
- Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.Digestive diseases and sciences · 2016Article
- Economic evaluation of genetic screening for Lynch syndrome in Germany.Genetics in medicine : official journal of the American College of Medical Genetics · 2015Article
- A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.BMC cancer · 2015Article
- When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.Healthcare (Basel, Switzerland) · 2015Article
- Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome.Digestive diseases and sciences · 2014Article
- UK colorectal cancer patients are inadequately assessed for Lynch syndrome.Frontline gastroenterology · 2014Article
- Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore.Familial cancer · 2012Article
- Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.Annals of internal medicine · 2011Article
- Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders.European journal of human genetics : EJHG · 2011Review
- Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.Cancer prevention research (Philadelphia, Pa.) · 2011Article
- Challenges of translating genetic tests into clinical and public health practice.Nature reviews. Genetics · 2009Review
- EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.Genetics in medicine : official journal of the American College of Medical Genetics · 2009Review
- Clinical guidelines versus universal molecular testing: are we ready to choose an optimal strategy for Lynch syndrome identification?The American journal of gastroenterology · 2008Article
- Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.Current opinion in molecular therapeutics · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThere is uncertainty regarding the optimal strategy for identifying mutation carriers among those with hereditary nonpolyposis colorectal cancer (HNPCC).
methodsWe used decision analysis to compare the cost-effectiveness of 4 strategies among those with newly diagnosed colon cancer: (1) clinical and family history followed by microsatellite instability testing and germline testing (Bethesda guidelines); (2) universal microsatellite instability testing; (3) germline testing of those who meet clinical and family history criteria; and (4) universal germline testing.
resultsThe added cost per year of life saved (YLS) for each strategy was as follows: (1) 11,865 US dollars/YLS, (2) 35,617 US dollars/YLS, (3) 49,702 US dollars/YLS, and (4) 267,548 US dollars/YLS.
conclusionsThe Bethesda guidelines are the most cost-effectiveness approach to screen persons for HNPCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.